Phase I/II randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke

Figure 1 Workup schema for patients recruited to the clinical trial of autologous mesenchymal stem cell therapy. MSC: Mesenchymal stem cell; MRI: Magnetic resonance imaging.

Figure 2 A representative image of mesenchymal stem cells at passage-8 captured under phase-contrast microscopy (left panel) and immunofluorescence staining of stage-specific embryonic antigen SSEA-4, transcription factor Oct-4 and neural stem cell marker Nestin (green fluorescence) with nuclei counterstained by DAPI (blue fluorescence).

Figure 3 Representative histograms derived from infusates by flow cytometric analyses of mesenchymal stem cell markers CD29, CD44, CD73, CD90, CD105 and CD166 (A) and haemic markers HLA-DR, CD45, CD3, CD19, CD16, CD33, CD38, CD34 and CD133 (B). FITC conjugation in blue and PE conjugation in purple.